VERAXA Biotech AG (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (bsADC) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products. This advancement underscores the potential of combining innovative platforms to address challenges in oncology.
The development of VXA-222 is significant because it represents a strategic effort to enhance the therapeutic index of ADCs. Traditional ADCs deliver potent cytotoxic drugs to cancer cells, but their efficacy can be limited by on-target, off-tumor toxicity. By employing a bispecific format that requires binding to two antigens for activation, VXA-222 aims to increase tumor selectivity and reduce side effects. This approach could broaden the applicability of ADCs to a wider range of solid tumors, which have historically been more challenging to treat with this modality.
For VERAXA, this milestone strengthens its pipeline of next-generation antibody-based therapeutics. The company is building a premier engine for discovery and development, including bispecific T cell engagers and bispecific ADCs. Founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA applies rigorous quality-by-design principles to rapidly advance its candidates into clinical development. The collaboration with OmniAb provides access to validated antibody discovery technologies, accelerating the path from target identification to lead candidate.
For OmniAb, the successful completion of discovery work for VXA-222 demonstrates the utility of its OmniClic platform in enabling complex bispecific formats. OmniAb’s technology leverages genetic engineering to generate diverse antibody repertoires, facilitating the selection of optimal binders for challenging targets. This collaboration exemplifies how OmniAb’s capabilities can be integrated with partners’ proprietary technologies to create novel therapeutics.
The implications of this announcement extend to the broader biopharmaceutical industry, as bispecific ADCs represent a frontier in targeted cancer therapy. If successful, VXA-222 could validate the AND-gate concept and encourage further investment in multispecific approaches. Additionally, the revenue-sharing structure between VERAXA and OmniAb provides a model for collaborative innovation, where both parties contribute essential technologies and share in the potential upside.
VERAXA’s progress also highlights the growing trend of leveraging external expertise to de-risk drug development. By partnering with OmniAb, the company has accessed world-class antibody discovery without the need to build internal capabilities from scratch. This strategy allows smaller biotech firms to compete with larger players in the development of advanced therapeutics.
Investors and industry observers will watch for further updates on VXA-222 as it enters the next phase, which likely includes lead optimization and preclinical studies. The success of this program could have significant implications for both companies, potentially leading to new treatment options for patients with solid tumors.
